메뉴 건너뛰기




Volumn 30, Issue 5, 2006, Pages 625-631

Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines

Author keywords

CD20 expression; CD55 and CD59 expression; Rituximab resistance

Indexed keywords

CD20 ANTIBODY; CD59 ANTIGEN; DECAY ACCELERATING FACTOR; MONOCLONAL ANTIBODY; RITUXIMAB;

EID: 33644866786     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2005.09.008     Document Type: Article
Times cited : (85)

References (31)
  • 1
    • 0028057250 scopus 로고
    • Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
    • M.E. Reff, K. Carner, K.S. Chambers, P.C. Chinn, J.E. Leonard, and R. Raab Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20 Blood 83 1994 435 445
    • (1994) Blood , vol.83 , pp. 435-445
    • Reff, M.E.1    Carner, K.2    Chambers, K.S.3    Chinn, P.C.4    Leonard, J.E.5    Raab, R.6
  • 2
    • 0034777814 scopus 로고    scopus 로고
    • CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells
    • N. Selenko, O. Maidic, S. Draxier, A. Berer, U. Jäger, and W. Knapp CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells Leukemia 15 2001 1619 1626
    • (2001) Leukemia , vol.15 , pp. 1619-1626
    • Selenko, N.1    Maidic, O.2    Draxier, S.3    Berer, A.4    Jäger, U.5    Knapp, W.6
  • 3
    • 0034671315 scopus 로고    scopus 로고
    • Anti-CD20- and B-cell receptor-mediated apoptosis: Evidence for shared intracellular signaling pathways
    • S. Mathas, A. Rickers, K. Bommert, B. Dorken, and M.Y. Mapara Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways Cancer Res 60 2000 7170 7176
    • (2000) Cancer Res , vol.60 , pp. 7170-7176
    • Mathas, S.1    Rickers, A.2    Bommert, K.3    Dorken, B.4    Mapara, M.Y.5
  • 4
    • 0034104375 scopus 로고    scopus 로고
    • Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells
    • D. Shan, J.A. Ledbetter, and O.W. Press Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells Cancer Immunol Immunother 48 2000 673 683
    • (2000) Cancer Immunol Immunother , vol.48 , pp. 673-683
    • Shan, D.1    Ledbetter, J.A.2    Press, O.W.3
  • 5
    • 17144455839 scopus 로고    scopus 로고
    • IDEC-C2B8: Result of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma
    • D.G. Maloney, A.J. Grillo-Lopez, D.J. Bodkin, C.A. White, T.M. Liles, and I. Royston IDEC-C2B8: result of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma J Clin Oncol 15 1997 3266 3274
    • (1997) J Clin Oncol , vol.15 , pp. 3266-3274
    • Maloney, D.G.1    Grillo-Lopez, A.J.2    Bodkin, D.J.3    White, C.A.4    Liles, T.M.5    Royston, I.6
  • 6
    • 0345337254 scopus 로고    scopus 로고
    • Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
    • P. McLaughlin, A.J. Grillo-Lopez, B.K. Link, R. Levy, M.S. Czuczman, and M.E. Williams Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program J Clin Oncol 16 1998 2825 2833
    • (1998) J Clin Oncol , vol.16 , pp. 2825-2833
    • McLaughlin, P.1    Grillo-Lopez, A.J.2    Link, B.K.3    Levy, R.4    Czuczman, M.S.5    Williams, M.E.6
  • 7
    • 0033968522 scopus 로고    scopus 로고
    • European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma
    • J.M. Foran, A.Z. Rohatiner, D. Cunningham, R.A. Popescu, P. Solal-Celigny, and M. Ghielmini European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma J Clin Oncol 18 2000 317 324
    • (2000) J Clin Oncol , vol.18 , pp. 317-324
    • Foran, J.M.1    Rohatiner, A.Z.2    Cunningham, D.3    Popescu, R.A.4    Solal-Celigny, P.5    Ghielmini, M.6
  • 8
    • 0032791210 scopus 로고    scopus 로고
    • Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma
    • L.D. Piro, C.A. White, A.J. Grillo-Lopez, N. Janakiraman, A. Saven, and T.M. Beck Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma Ann Oncol 10 1999 655 661
    • (1999) Ann Oncol , vol.10 , pp. 655-661
    • Piro, L.D.1    White, C.A.2    Grillo-Lopez, A.J.3    Janakiraman, N.4    Saven, A.5    Beck, T.M.6
  • 9
    • 7844225540 scopus 로고    scopus 로고
    • Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma
    • N.L. Berinstein, A.J. Grillo-Lopez, C.A. White, I. Bence-Bruckler, D. Maloney, and M. Czuczman Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma Ann Oncol 9 1998 995 1001
    • (1998) Ann Oncol , vol.9 , pp. 995-1001
    • Berinstein, N.L.1    Grillo-Lopez, A.J.2    White, C.A.3    Bence-Bruckler, I.4    Maloney, D.5    Czuczman, M.6
  • 10
    • 0032530342 scopus 로고    scopus 로고
    • Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study
    • B. Coiffier, C. Haioun, N. Ketterer, A. Engert, H. Tilly, and D. Ma Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study Blood 92 1998 1927 1932
    • (1998) Blood , vol.92 , pp. 1927-1932
    • Coiffier, B.1    Haioun, C.2    Ketterer, N.3    Engert, A.4    Tilly, H.5    Ma, D.6
  • 11
    • 0037165261 scopus 로고    scopus 로고
    • CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma
    • B. Coiffier, E. Lepage, J. Briere, R. Herbrecht, H. Tilly, and R. Bouabdallah CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma N Engl J Med 346 2002 235 242
    • (2002) N Engl J Med , vol.346 , pp. 235-242
    • Coiffier, B.1    Lepage, E.2    Briere, J.3    Herbrecht, R.4    Tilly, H.5    Bouabdallah, R.6
  • 12
    • 0037698992 scopus 로고    scopus 로고
    • Rituximab plus CHOP (R-CHOP) overcomes bcl-2 - Associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)
    • N. Mounier, J. Briere, C. Gisselbrecht, J.F. Emile, P. Lederlin, and C. Sebban Rituximab plus CHOP (R-CHOP) overcomes bcl-2 - associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL) Blood 101 2003 4279 4284
    • (2003) Blood , vol.101 , pp. 4279-4284
    • Mounier, N.1    Briere, J.2    Gisselbrecht, C.3    Emile, J.F.4    Lederlin, P.5    Sebban, C.6
  • 13
    • 4344660758 scopus 로고    scopus 로고
    • Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma
    • P.L. Zinzani, A. Pulsoni, A. Perrotti, S. Soverini, F. Zaja, and A. De Renzo Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma J Clin Oncol 22 2004 2654 2661
    • (2004) J Clin Oncol , vol.22 , pp. 2654-2661
    • Zinzani, P.L.1    Pulsoni, A.2    Perrotti, A.3    Soverini, S.4    Zaja, F.5    De Renzo, A.6
  • 14
    • 13244270361 scopus 로고    scopus 로고
    • CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma
    • R. Marcus, K. Imrie, A. Belch, D. Cunningham, E. Flores, and J. Catalano CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma Blood 105 2005 1417 1423
    • (2005) Blood , vol.105 , pp. 1417-1423
    • Marcus, R.1    Imrie, K.2    Belch, A.3    Cunningham, D.4    Flores, E.5    Catalano, J.6
  • 15
    • 9444247655 scopus 로고    scopus 로고
    • Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: A prospective, multicenter phase II study
    • W. Brugger, J. Hirsch, F. Grunebach, R. Repp, P. Brossart, and W. Vogel Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study Ann Oncol 15 2004 1691 1698
    • (2004) Ann Oncol , vol.15 , pp. 1691-1698
    • Brugger, W.1    Hirsch, J.2    Grunebach, F.3    Repp, R.4    Brossart, P.5    Vogel, W.6
  • 16
    • 13244288836 scopus 로고    scopus 로고
    • Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up
    • M.S. Czuczman, R. Weaver, B. Alkuzweny, J. Berlfein, and A.J. Grillo-Lopez Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up J Clin Oncol 22 2004 4711 4716
    • (2004) J Clin Oncol , vol.22 , pp. 4711-4716
    • Czuczman, M.S.1    Weaver, R.2    Alkuzweny, B.3    Berlfein, J.4    Grillo-Lopez, A.J.5
  • 17
    • 14944343819 scopus 로고    scopus 로고
    • Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: A phase II trial of the minnie pearl cancer research network
    • J.D. Hainsworth, S. Litchy, L.H. Morrissey, M.B. Andrews, M. Grimaldi, and M. McCarty Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the minnie pearl cancer research network J Clin Oncol 23 2005 1500 1506
    • (2005) J Clin Oncol , vol.23 , pp. 1500-1506
    • Hainsworth, J.D.1    Litchy, S.2    Morrissey, L.H.3    Andrews, M.B.4    Grimaldi, M.5    McCarty, M.6
  • 18
    • 14544274608 scopus 로고    scopus 로고
    • Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders
    • L.N. Gordan, W.B. Grow, A. Pusateri, V. Douglas, N.P. Mendenhall, and J.W. Lynch Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders J Clin Oncol 23 2005 1096 1102
    • (2005) J Clin Oncol , vol.23 , pp. 1096-1102
    • Gordan, L.N.1    Grow, W.B.2    Pusateri, A.3    Douglas, V.4    Mendenhall, N.P.5    Lynch, J.W.6
  • 19
    • 20044362555 scopus 로고    scopus 로고
    • Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: A phase II trial in the North Central Cancer Treatment Group
    • T.E. Witzig, A.M. Vukov, T.M. Habermann, S. Geyer, P.J. Kurtin, and W.R. Friedenberg Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group J Clin Oncol 23 2005 1103 1108
    • (2005) J Clin Oncol , vol.23 , pp. 1103-1108
    • Witzig, T.E.1    Vukov, A.M.2    Habermann, T.M.3    Geyer, S.4    Kurtin, P.J.5    Friedenberg, W.R.6
  • 20
    • 0034999619 scopus 로고    scopus 로고
    • Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies
    • S.P. Treon, C. Mitsiades, N. Mitsiades, G. Young, D. Doss, and R. Schlossman Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies J Immunother 24 2001 263 271
    • (2001) J Immunother , vol.24 , pp. 263-271
    • Treon, S.P.1    Mitsiades, C.2    Mitsiades, N.3    Young, G.4    Doss, D.5    Schlossman, R.6
  • 21
    • 0035760902 scopus 로고    scopus 로고
    • CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: Further regulation by CD55 and CD59
    • J. Golay, M. Lazzari, V. Faccinetti, S. Bernasconi, G. Borleri, and T. Barbui CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59 Blood 98 2001 3383 3389
    • (2001) Blood , vol.98 , pp. 3383-3389
    • Golay, J.1    Lazzari, M.2    Faccinetti, V.3    Bernasconi, S.4    Borleri, G.5    Barbui, T.6
  • 22
    • 0035469885 scopus 로고    scopus 로고
    • Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma
    • W.K. Weng, and R. Levy Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma Blood 98 2001 1352 1357
    • (2001) Blood , vol.98 , pp. 1352-1357
    • Weng, W.K.1    Levy, R.2
  • 23
    • 0034660092 scopus 로고    scopus 로고
    • Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis
    • J. Golay, L. Zaffaroni, T. Vaccari, M. Lazzari, G.M. Borleri, and S. Bernasconi Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis Blood 95 2000 3900 3908
    • (2000) Blood , vol.95 , pp. 3900-3908
    • Golay, J.1    Zaffaroni, L.2    Vaccari, T.3    Lazzari, M.4    Borleri, G.M.5    Bernasconi, S.6
  • 24
    • 0037306893 scopus 로고    scopus 로고
    • In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas
    • O. Manches, G. Lui, L. Chaperot, R. Gressin, J.P. Molens, and M.C. Jacob In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas Blood 101 2003 949 954
    • (2003) Blood , vol.101 , pp. 949-954
    • Manches, O.1    Lui, G.2    Chaperot, L.3    Gressin, R.4    Molens, J.P.5    Jacob, M.C.6
  • 25
    • 0036123109 scopus 로고    scopus 로고
    • CD20-negative relapse of cutaneous B-cell lymphoma after anti-CD20 monoclonal antibody therapy
    • W.T. Massengale, E. McBurney, and J. Gurtler CD20-negative relapse of cutaneous B-cell lymphoma after anti-CD20 monoclonal antibody therapy J Am Acad Dermatol 46 2002 441 443
    • (2002) J Am Acad Dermatol , vol.46 , pp. 441-443
    • Massengale, W.T.1    McBurney, E.2    Gurtler, J.3
  • 26
    • 0033055251 scopus 로고    scopus 로고
    • Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression
    • T.A. Davis, D.K. Czerwinski, and R. Levy Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression Clin Cancer Res 5 1999 611 615
    • (1999) Clin Cancer Res , vol.5 , pp. 611-615
    • Davis, T.A.1    Czerwinski, D.K.2    Levy, R.3
  • 27
    • 0032406790 scopus 로고    scopus 로고
    • CD20-negative relapse in B-cell lymphoma after treatment with rituximab
    • T. Kinoshita, H. Nagai, T. Murate, and H. Saito CD20-negative relapse in B-cell lymphoma after treatment with rituximab J Clin Oncol 16 1998 3916
    • (1998) J Clin Oncol , vol.16 , pp. 3916
    • Kinoshita, T.1    Nagai, H.2    Murate, T.3    Saito, H.4
  • 28
    • 0032821561 scopus 로고    scopus 로고
    • Clonal selection of CD20-negative non-Hodgkin's lymphoma cells after treatment with anti-CD20 antibody rituximab
    • K. Schmitz, W. Brugger, B. Weiss, E. Kaiserling, and L. Kanz Clonal selection of CD20-negative non-Hodgkin's lymphoma cells after treatment with anti-CD20 antibody rituximab Br J Haematol 106 1999 571 572
    • (1999) Br J Haematol , vol.106 , pp. 571-572
    • Schmitz, K.1    Brugger, W.2    Weiss, B.3    Kaiserling, E.4    Kanz, L.5
  • 29
    • 0036023451 scopus 로고    scopus 로고
    • Intracellular accumulation of the anti-CD20 antibody 1F5 in B-lymphoma cells
    • R.B. Michel, and M.J. Mattes Intracellular accumulation of the anti-CD20 antibody 1F5 in B-lymphoma cells Clin Cancer Res 8 2002 2701 2713
    • (2002) Clin Cancer Res , vol.8 , pp. 2701-2713
    • Michel, R.B.1    Mattes, M.J.2
  • 30
    • 0028263670 scopus 로고
    • Modulation and intracellular transport of CD20 and CD21 antigens induced by B1 and B2 monoclonal antibodies in RAJI and JOK-1 cells - An immunofluorescence and immunoelectron microscopy study
    • S. Pulczynski, A.M. Boesen, and O.M. Jensen Modulation and intracellular transport of CD20 and CD21 antigens induced by B1 and B2 monoclonal antibodies in RAJI and JOK-1 cells - an immunofluorescence and immunoelectron microscopy study Leuk Res 18 1994 541 552
    • (1994) Leuk Res , vol.18 , pp. 541-552
    • Pulczynski, S.1    Boesen, A.M.2    Jensen, O.M.3
  • 31
    • 0242492546 scopus 로고    scopus 로고
    • Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia
    • I. Jilani, S. O'Brien, T. Manshuri, D.A. Thomas, V.A. Thomazy, and M. Imam Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia Blood 102 2003 3514 3520
    • (2003) Blood , vol.102 , pp. 3514-3520
    • Jilani, I.1    O'Brien, S.2    Manshuri, T.3    Thomas, D.A.4    Thomazy, V.A.5    Imam, M.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.